EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gemcitabine activates the Hippo signaling pathway and suppresses tumor growth by stabilizing large tumor suppressor kinase 2 through the hypoxia‐inducible factor 1‐alpha/ubiquitin protein ligase E3 component N‐recognin 5 axis

Jin Zhang, Lixia Xu, Kai Guo, Weijia Dong, Xin Dai, Donghua Gu iD

Journal of Cell Communication and Signaling · 2026-06 · 20 (2)

DOI: 10.1002/ccs3.70085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cell Communication and Signaling, online erschienen am 17.06.2026. Verfasst von Jin Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology Suzhou Science & Technology Town Hospital Suzhou China. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To investigate the molecular mechanism by which gemcitabine (GEM) inhibits ovarian cancer (OC) progression, focusing on the hypoxia‐inducible factor 1‐alpha (HIF1A)/UBR5/LATS2 axis and Hippo pathway. Bioinformatics analysis of gene expression omnibus datasets identified HIF1A‐associated modules. Transcriptional regulation of UBR5 by HIF1A was validated via ChIP‐PCR and dual‐luciferase assays. Anti‐tumor effects of GEM were assessed in OC cell lines and an orthotopic mouse model using functional assays (CCK‐8, transwell), Western blot, Co‐IP, and ubiquitination analysis. HIF1A transcriptionally upregulates UBR5 in OC. GEM downregulated the HIF1A/UBR5 axis, suppressing OC cell proliferation, migration, and invasion. Mechanistically, UBR5 promoted LATS2 ubiquitination and degradation. GEM inhibited this interaction, stabilizing LATS2, activating the Hippo pathway, and suppressing downstream YAP1/FGFR1 signaling. In vivo, GEM inhibited tumor growth and downregulated HIF1A, UBR5, and FGFR1. GEM suppresses OC progression by targeting the HIF1A/UBR5 axis, which subsequently stabilizes LATS2, activates the Hippo pathway, and inhibits YAP1/FGFR1 signaling, revealing a novel therapeutic mechanism.

Schlagwörter

Stichwörter der Autor:innen

HIF1AHippo signaling pathwayUBR5gemcitabineovarian cancer

Autor:innen und Institutionen

  • Department of Pathology Suzhou Science & Technology Town Hospital Suzhou China.
  • Department of Pathology Huzhou Central Hospital Huzhou China.
  • Department of Pathology School of Medicine Huzhou University Huzhou China.

ORCID-Profile: Donghua Gu

Zitieren

APA

Zhang, J., Xu, L., Guo, K., Dong, W., Dai, X., & Gu, D. (2026). Gemcitabine activates the Hippo signaling pathway and suppresses tumor growth by stabilizing large tumor suppressor kinase 2 through the hypoxia‐inducible factor 1‐alpha/ubiquitin protein ligase E3 component N‐recognin 5 axis. Journal of Cell Communication and Signaling, 20(2). https://doi.org/10.1002/ccs3.70085

Vancouver

Zhang J, Xu L, Guo K, Dong W, Dai X, Gu D. Gemcitabine activates the Hippo signaling pathway and suppresses tumor growth by stabilizing large tumor suppressor kinase 2 through the hypoxia‐inducible factor 1‐alpha/ubiquitin protein ligase E3 component N‐recognin 5 axis. Journal of Cell Communication and Signaling. 2026;20(2). doi:10.1002/ccs3.70085

BibTeX
@article{Zhang2026,
  author = {Zhang, Jin and Xu, Lixia and Guo, Kai and Dong, Weijia and Dai, Xin and Gu, Donghua},
  title = {Gemcitabine activates the Hippo signaling pathway and suppresses tumor growth by stabilizing large tumor suppressor kinase 2 through the hypoxia‐inducible factor 1‐alpha/ubiquitin protein ligase E3 component N‐recognin 5 axis},
  journal = {Journal of Cell Communication and Signaling},
  year = {2026},
  volume = {20},
  number = {2},
  doi = {10.1002/ccs3.70085}
}
Kostenlos starten →